南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

表观遗传调节因子ALKBH5促进肝细胞癌细胞对索拉非尼治疗的早期适应

The epigenetic regulator ALKBH5 facilitates the early adaptation of hepatocellular carcinoma cells to sorafenib treatment

Meng Li, Jiayu Wang, Shuai Fang, Lu Dai, Xilin Sun, Fei Sun, Wei Huang

Journal:JOURNAL OF CHEMOTHERAPY

IF:2.1

DOI:10.1080/1120009X.2026.2722741

PMID:42691501

Published:2026-09-03

research field:分子生物学药理学细胞生物学炎症研究结构生物学骨科生物化学

Abstract

Hepatocellular carcinoma (HCC) frequently develops resistance to tyrosine kinase inhibitors (TKIs) like sorafenib – the first FDA-approved systemic therapy for advanced HCC – yet early resistance mechanisms remain unclear. Short-term sorafenib exposure in sensitive HCC cells induces global m6A reduction and rapid upregulation of the demethylase ALKBH5. High ALKBH5 expression correlates with poor prognosis in sorafenib-treated HCC patients. Functionally, ALKBH5 overexpression enhances sorafenib resistance, clonogenicity and epithelial-mesenchymal transition (EMT) by stabilizing β-catenin and activating Wnt/β-catenin signalling. Thus, ALKBH5 is a key early driver of sorafenib resistance via the Wnt/β-catenin pathway and may serve as both a prognostic biomarker and therapeutic target in HCC.

本文使用的Yeasen产品

购物车
客服
转染试用